Kelly A. Kramer sold $713k of GILD
director at GILEAD SCIENCES, INC.. 5,611 shares at an average of $127.11, traded Nov 26, 2025, filed Dec 1, 2025.
Score components
- +15RoleDirector
- +21Trade size$713k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.6%, 3m +21.5%, 6m +6.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001629885-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 26, 2025 | MOption exercise Common Stock10b5-1 | +2,806 | $81.00 | $227k | 4,145 | Dec 1, 2025 |
| Nov 26, 2025 | SOpen-market sale Common Stock10b5-1 | -2,806 | $127.11 | $357k | 1,339 | Dec 1, 2025 |
| Nov 28, 2025 | MOption exercise Common Stock10b5-1 | +2,805 | $81.00 | $227k | 4,144 | Dec 1, 2025 |
| Nov 28, 2025 | SOpen-market sale Common Stock10b5-1 | -2,805 | $127.10 | $357k | 1,339 | Dec 1, 2025 |
| Nov 26, 2025 | MOption exercise Non-qualified Stock Option (Right to Buy)derivative10b5-1 | -2,806 | $0.00 | $0 | 2,805 | Dec 1, 2025 |
| Nov 28, 2025 | MOption exercise Non-qualified Stock Option (Right to Buy)derivative10b5-1 | -2,805 | $0.00 | $0 | 0 | Dec 1, 2025 |
Related signals
Other insiders at GILEAD SCIENCES, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GILEAD SCIENCES, INC. | Daniel Patrick O'Day Chairman & CEO | $2.2M 15,000 shares | -3% | |
| 34Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $436k 3,000 shares | -2% | |
| 27Weak | GILEAD SCIENCES, INC. | Johanna Mercier Chief Comm & Corp Aff Officer | $433k 3,000 shares | -3% | |
| 45Moderate | GILEAD SCIENCES, INC. | Daniel Patrick O'Day Chairman & CEO | $2.2M 15,000 shares | -3% | |
| 40Moderate | GILEAD SCIENCES, INC. | Anthony Welters director | $2.7M 18,000 shares | -87% | |
| 26Weak | GILEAD SCIENCES, INC. | Jeffrey Bluestone director | $725k 5,000 shares | -45% | |
| 33Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $415k 3,000 shares | -2% | |
| 25Weak | GILEAD SCIENCES, INC. | Johanna Mercier Chief Comm & Corp Aff Officer | $3.9M 28,000 shares | -19% | |
| 45Moderate | GILEAD SCIENCES, INC. | Daniel Patrick O'Day Chairman & CEO | $2.0M 15,000 shares | -2% | |
| 33Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $390k 3,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.